drugset
drugset / Trial / NCT05222438

Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

NCT05222438 ↗

Phase 2 Withdrawn Barbara Ann Karmanos Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

Study of loncastuximab tesirine administered intravenously (IV) for maintenance therapy following autologous stem cell transplant in patients with relapsed diffuse large B cell lymphoma

Timeline

Start
2022-04-08
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Loncastuximab Tesirine Other / unclassified 75 ug/kg Intravenous

Indications

diffuse large B-cell lymphoma